Polaryx Therapeutics (NASDAQ:PLYX) Stock Price Down 1.9% – Time to Sell?

Polaryx Therapeutics, Inc. (NASDAQ:PLYX) shares fell 1.9% during mid-day trading on Friday . The company traded as low as $5.11 and last traded at $5.54. 1,158,292 shares were traded during trading, a decline of 63% from the average session volume of 3,144,816 shares. The stock had previously closed at $5.65.

Analyst Upgrades and Downgrades

Separately, Maxim Group started coverage on shares of Polaryx Therapeutics in a research note on Friday, February 27th. They issued a “buy” rating and a $10.00 target price for the company. One equities research analyst has rated the stock with a Buy rating, According to data from MarketBeat.com, Polaryx Therapeutics presently has an average rating of “Buy” and an average target price of $10.00.

Polaryx Therapeutics Trading Down 1.9%

About Polaryx Therapeutics

We are a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders (“LSDs”). Our therapeutic philosophy is centered on delivering safe, effective, and patient-friendly treatments that address the underlying pathophysiology of these catastrophic diseases and their significant unmet need. Our multi-modal approach integrates small molecule therapies, including a combination therapy, and a gene therapy, positioning us to potentially address both the genetic and downstream pathological features of LSDs.